CREAMFINANCE
7.2.2020 10:14:07 CET | Business Wire | Press release
Patrick Koeck, the new CEO of Creamfinance as of 15th January, has set a goal to expand the business consistently at around 20% per annum and aims to grow sustainably above €100M annual revenue within two years despite the complex regulatory landscape.
“Staying ahead of ever-changing regulations is tough and operating across EU and Latam requires a lot of effort. Strong focus on operations and a steady launch of our full product offer across all of our markets is in my view critical at this stage of our company’s growth,” Koeck commented.
The company is said to have gone through a hyper-growth phase having raised over EUR100M in funding with over 3.6M registered users and EUR700M in issued loans across 7 countries. It has now entered a mature state where the key focus is set on risk management, operational excellence and efficiency. The skillset of the new CEO is expected to enable Creamfinance to grow steadily and consistently.
Koeck has previously worked as a Chief Operating Officer, being part of the company’s core team for over 6 years.
“It is an honor to gain confidence from the co-founders, who have been great mentors to me, to lead Creamfinance to the next level. I am looking forward to cooperating with the team to pursue significant growth opportunities ahead and I am certain that it will lead to stable long term profits,” Koeck said in a recent statement.
The former CEO, Matiss Ansviesulis and the Chairman of the Board, Davis Barons, reflected that for the past 8 years Creamfinance has been their life with many ups and downs. During that period they have not only built a sizeable business, but were also very fortunate to have worked with some very talented people from all over the world. “However, now we recognize that the team we have built is capable of taking the company to the next level on its own. We feel that our company is well positioned,” Ansviesulis concluded.
The company stated that both co-founders remain with Creamfinance as Board Members and will continue working on creating new business opportunities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200207005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Agency Launches to Empower Creators Across Entertainment-Based Intellectual Property5.3.2026 16:23:00 CET | Press release
New Service Simplifies Access to Premium IP Licensing, Driving Discoverability, Player Engagement, and Revenue for Game Developers Xsolla, a global video game commerce company, today launched Xsolla Agency, a comprehensive service connecting game developers with premium entertainment-based intellectual property (IP). The integrated offering addresses critical challenges for game creators: access to world-class IP, global monetization capabilities, and the operational infrastructure needed to build sustainable businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305044119/en/ Graphic: Xsolla Xsolla Agency simplifies access to entertainment-based licenses through expert-led negotiations and industry relationships, offering affordable, monetization-focused deals structured for maximum ROI. Strategic IP partnerships increase discoverability, reduce user acquisition costs, and drive higher player spend through impactful
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures5.3.2026 16:00:00 CET | Press release
-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX--These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatment (up to 14 days), demonstrating the potential for JOURNAVX as a core element of opioid-free multimodal treatment for moderate-to-severe acute pain after aesthetic and reconstructive procedures. In contrast, the literature shows opioid-free rates of less than 10% with multimodal treatment without JOURNAVX. These dat
Onego Bio and Sigma Foods Enter Collaboration to Strengthen Egg Protein Innovation and Supply Resilience5.3.2026 16:00:00 CET | Press release
Onego Bio, a food ingredient company producing non-animal egg protein, and Sigma Foods ("SIGMA"), a leading multinational food company, have entered into a collaboration agreement to evaluate the functionality and commercial potential of Bioalbumen®, a non-animal egg protein made with using precision fermentation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305756400/en/ The partnership focuses on advancing ingredient innovation while addressing urgent challenges in today’s egg supply chain—including volatility, rising prices, and avian flu-related disruptions. Bioalbumen® offers a shelf-stable, animal-free alternative that delivers the same functional, nutritional, and sensory performance as traditional eggs, while helping safeguard supply continuity for food manufacturers. Additionally, this collaboration supports Sigma’s commitment to offering safe, nutritious, and high-quality food, while driving science-based inno
Ushio Completes Acquisition of OSRAM Entertainment and Industry Business5.3.2026 15:08:00 CET | Press release
Business to operate globally as Ushio Industry & Entertainment Ushio Inc. today announced the successful completion of the acquisition of the OSRAM Entertainment and Industry (ENI) business. As of March 2, 2026, the business officially operates as part of the Ushio Group under the name Ushio INE GmbH (hereinafter: Ushio Industry & Entertainment). This strategic acquisition strengthens Ushio’s global position in specialty lighting and expands its capabilities across entertainment, cinema projection, stage lighting, industrial applications, and high-performance professional solutions. The newly integrated organization combines Ushio’s established technology portfolio and global manufacturing strength with the long-standing expertise, customer relationships, and application knowledge of the former OSRAM Entertainment and Industry team. Marko Haas, General Manager of Business Division of Ushio Industry & Entertainment, commented: “This marks an important milestone for our business and our
Adaptive announces strategic investment from HSBC and Citi to fuel capital markets technology innovation5.3.2026 14:01:00 CET | Press release
Investment capitalizes on significant technological shifts in capital markets driven by cloud, open-source and AIFunding to scale Adaptive’s development of next-gen cloud-enabled front office solutions, centered around its Aeron® technology Adaptive, a leader in custom trading technology solutions, announces it has secured strategic investment from two prominent global financial institutions, Citi and HSBC. This funding is set to significantly accelerate Adaptive’s growth and product innovation roadmap. The strategic backing from HSBC and Citi underscores the collaboration between Adaptive and two of the world’s largest financial institutions on strategic initiatives to reshape capital markets technology. It will enable Adaptive to capitalize on significant technological disruption and meet the growing demand for client‑owned, differentiated and bespoke trading technology. Centered around Adaptive’s suite of Aeron®products, the funding allows the company to scale its delivery of high-p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom